Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin

Supportive Care in Cancer

Volumn 5, Issue 2, 1997, Pages 126-129

  Lissoni, P ^a   Tancini, G ^a   Barni, S ^a   Paolorossi, F ^a   Ardizzoia, A ^a   Conti, A ^b   Maestroni, G ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Chemotherapy; Melatonin; Myelosuppression; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOLIC ACID; MELATONIN; MITOXANTRONE; PINEAL BODY HORMONE;

ADULT; AGED; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; NEUROPATHY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA;

EID: 0030974891     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01262569     Document Type: Article

References (10)

1. Arendt J (1988) Melatonin. Clin Endocrinol 29:205-229
2. Hill SM, Spriggs LL, Simon MA, Muraoka H, Blask DE (1992) The growth inhibitory action of melatonin on human breast cancer is linked to the oestrogen response system. Cancer Lett 64:249-256
3. Hrushesky WJM, Langer R, Theeuwes F (1991) Temporal control of drug delivery. Ann N Y Acad Sci 618:641-645
4. Lissoni P, Barni S, Tancini G, et al (1994) A randomised study with subcutaneous low-dose interleukin-2 alone vs interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 69:196-199
5. Maestroni GJM, Conti A, Pierpaoli W (1988) Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. Ann N Y Acad Sci: 140-148
6. Maestroni GJM, Conti A, Lissoni P (1994) Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin-4. Cancer Res 54:4740-4744
7. Poeggler B, Reiter RJ, Tan DX, Chen LD, Manchester LC (1993) Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. J Pineal Res 14:151-168
8. Regelson W, Pierpaoli W (1987) Melatonin: a rediscovered antitumor hormone? Its relation to surface receptors, sex, steroid metabolism, immunologic response and chronobiological factors in tumor growth and therapy. Cancer Invest 5:379-385
9. Smythe GA, Stuart MC, Lazarus I (1974) Stimulation and suppression of somatomedin activity by serotonin and melatonin. Experientia 30:1356-1358
10. Viviani S, Negretti E, Orazi A, et al (1990) Preliminary studies on melatonin in the treatment of myelodys-plastic syndromes following cancer chemotherapy. J Pineal Res 8:347-351